ABO-202 STMN2 clinical clearance
Arbor identifies ABO-202 as an AAV-delivered nuclease-excision program for STMN2-related ALS. It is distinct from its C9ORF and UNC13A programs.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Source supports program identity and development context, not a scheduled authorization event; refresh stage and clinical record.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
IND-enabling program — decision date unconfirmed
Company context
Company-authored LinkedIn About explicitly states Type: Privately Held and links arbor.bio. Opened and checked October 31, 2026. This is an undated company self-report, not independent registry proof. The opened 2026 Metagenomi annual report also calls Arbor private.
Potential outcome market
Will Arbor publicly confirm clearance to begin human dosing of ABO-202 in ALS by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.